Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AZN

Astrazeneca plc

Apr 29 • 04:00PM ET

185.20

-1.48 -0.79 %

Healthcare • Drug Manufacturers - General • United Kingdom • Mega • NYSE

Today, 7:05 PMAstraZeneca posts Q1 2026 core EPS $2.58, revenue $15.29B, and exercises exclusive global PTX-299 license from Pinetree in collaboration valued at over $500 million

Held by: PVAL AVDE DIHP DFIC PPH PBPH FVD DFAX BDYN JDVL

Scroll to Statements

Index	-	P/E	28.27	EPS (ttm)	6.55	Insider Own	4.82%	Shs Outstand	1.55B	Perf Week	-4.93%
Market Cap	287.21B	Forward P/E	15.92	EPS next Y	11.63	Insider Trans	0.00%	Shs Float	1.48B	Perf Month	-4.48%
Enterprise Value	311.15B	PEG	1.31	EPS next Q	2.52	Inst Own	55.34%	Short Float	0.12%	Perf Quarter	-1.38%
Income	10.22B	P/S	4.89	EPS this Y	12.16%	Inst Trans	-12.88%	Short Ratio	0.85	Perf Half Y	12.93%
Sales	58.74B	P/B	5.90	EPS next Y	13.21%	ROA	9.38%	Short Interest	1.74M	Perf YTD	5.53%
Book/sh	31.38	P/C	50.03	EPS next 5Y	12.12%	ROE	22.86%	52W High	212.71 -12.93%	Perf Year	27.78%
Cash/sh	3.70	P/FCF	23.62	EPS past 3/5Y	45.90% 22.05%	ROIC	13.67%	52W Low	131.03 41.34%	Perf 3Y	26.37%
Dividend Est.	3.34 (1.80%)	EV/EBITDA	16.09	Sales past 3/5Y	9.82% 16.31%	Gross Margin	74.35%	Volatility	1.98% 1.72%	Perf 5Y	77.39%
Dividend TTM	3.20 (1.73%)	EV/Sales	5.30	EPS Y/Y TTM	45.27%	Oper. Margin	23.16%	ATR (14)	4.15	Perf 10Y	219.59%
Dividend Ex-Date	Feb 20, 2026	Quick Ratio	0.72	Sales Y/Y TTM	8.63%	Profit Margin	17.41%	RSI (14)	34.05	Recom	1.61
Dividend Gr. 3/5Y	1.78% 3.25%	Current Ratio	0.94	EPS Q/Q	54.97%	SMA20	-6.63%	Beta	0.31	Target Price	222.43
Payout	47.19%	Debt/Eq	0.61	Sales Q/Q	4.11%	SMA50	-5.96%	Rel Volume	2.16	Prev Close	186.68
Employees	96100	LT Debt/Eq	0.54	Earnings	Apr 29 BMO	SMA200	5.99%	Avg Volume	2.05M	Price	185.20
IPO	Oct 17, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.32% 0.38%	Trades		Volume	4,424,329	Change	-0.79%

Today 07:00PM	Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca (PR Newswire)
12:12PM	AstraZeneca to invest £300m in Britain as Starmer pays more for drugs (The Telegraph)
11:12AM	AstraZeneca beats Q1 estimates, CEO says drug pipeline is 'delivering' (Yahoo Finance Video)
08:06AM	Astrazeneca tops expectations in the first quarter on strong cancer drug sales (Associated Press)
07:58AM	AstraZeneca Q1 2026 earnings beat on cancer drug sales (Quartz)
07:21AM	Loading…
07:21AM	FDA tests out real-time clinical trials; AbbVie closes in on a KRAS biotech (BioPharma Dive)
06:09AM	American industry is winning: White House touts factory boom how investors can ride the reshoring wave (Moneywise)
03:09AM	AstraZeneca tops Q1 forecasts on strong cancer, rare-disease drug demand (Investing.com)
02:36AM	Astrazeneca: Q1 Earnings Snapshot (Associated Press)
02:16AM	FTSE 100 Live: Stocks sink as oil pushes 4yr highs, AstraZeneca, GSK, Lloyds report (Proactive)
02:16AM	FTSE 100 Live: Sluggish start as AstraZeneca, Haleon, St James Place fall (Proactive)
02:03AM	AstraZeneca sticks to its guns after strong first-quarter revenue growth (Proactive)
Apr-28-26 03:00PM	FDA is launching real-time monitoring of drug trials, with AstraZeneca and Amgen as first test cases (Quartz)
09:15AM	Earnings To Watch: AstraZeneca PLC (LSE:AZN) Reports Q1 2026 Result (GuruFocus.com)
05:55AM	FDA approves AstraZeneca's Saphnelo for SLE (Pharmaceutical Business Review)
02:06AM	Loading…
02:06AM	FTSE 100 Live: Barclays leads blue-chips lower after results, oil hits $110 a barrel (Proactive)
Apr-27-26 08:04AM	Citi sees Daiichi supply review as immaterial for AstraZeneca (Proactive)
07:00AM	SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus (Business Wire)
Apr-21-26 01:01PM	T Rowe Price Equity Income Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage (GuruFocus.com)
08:03AM	AstraZeneca's tozorakimab treble puts $5bn sales ceiling in sight, says Citi (Proactive)
03:16AM	AstraZeneca's Ultomiris hits primary endpoint in rare kidney disease trial (Proactive)
02:16AM	FTSE 100 Live: Stocks open flat as market awaits signals on Iran-US talks (Proactive)
02:16AM	FTSE 100 Live: London stocks mixed as bond markets eye Starmer pressure (Proactive)
Apr-20-26 07:00AM	Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD (Business Wire)
Apr-17-26 06:44AM	The innovators working to make in vivo cell therapy a reality (Pharmaceutical Technology)
Apr-15-26 03:17AM	FTSE 100 Live: Shares mixed as Iran talks awaited, Ceres and Rank jump (Proactive)
Apr-13-26 12:48PM	GSK Plans Five Late-Stage Cancer Trials As Shares Rise Nearly 50% (GuruFocus.com)
Apr-10-26 05:01PM	Parnassus Value Equity Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage (GuruFocus.com)
10:31AM	AstraZeneca faces China headwinds and key drug launches as two banks back 20% upside (Proactive)
Apr-08-26 08:09AM	Virginia governor signs 4 laws establishing manufacturing grant programs (Manufacturing Dive)
07:15AM	Loading…
Apr-07-26 07:15AM	FTSE 100 Live: Defence and gold miners drag as Trump's new Iran deadline awaited (Proactive)
07:00AM	AstraZeneca's liver cancer breakthrough puts Imfinzi on course to become a super-blockbuster drug (Proactive)
Apr-01-26 09:15AM	US bank sees AstraZeneca HPP drug data as supportive of $2.6bn forecast with upside to $4.4bn despite mixed trial results (Proactive)
Mar-31-26 03:45PM	$2 Billion Bayer Verdict: What the Roundup Decision Means for MAHA (Exec Edge)
09:04AM	Lilly's $2 Billion AI Deal Raises Stakes (GuruFocus.com)
Mar-30-26 10:15AM	Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients (Proactive)
05:23AM	FTSE 100 Live: Blue-chip index climbs as oil price rises but bonds ease (Proactive)
02:03AM	Connecting Excellence Group appoints chief performance and growth officer (Proactive)
Mar-27-26 07:00AM	Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD (Business Wire)
04:41AM	AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials (Proactive)
Mar-26-26 03:00PM	Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-24-26 10:30AM	Advancements in Novel Immunotherapeutics in The Oncology Battle (Newsfile)
Mar-19-26 11:39AM	Long-only funds are buying non-US stocks, BofA says (Investing.com)
03:22AM	AstraZeneca to boost cell therapy capabilities with new China investment (BioPharma Dive)
Mar-18-26 02:29PM	Analysis-TrumpRx lists many medicines at prices higher than paid in UK (Reuters)
Mar-16-26 07:02AM	Building materials giant abandons London stock market (The Telegraph)
07:02AM	£50bn construction giant abandons London stock market (The Telegraph)
Mar-12-26 02:55PM	Abivax Pushes Back On Takeover Rumors (Moby)
03:33AM	Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board (Proactive)
Mar-10-26 08:30AM	AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer (Business Wire)
Mar-09-26 09:35AM	Will Weak Gardasil Sales Continue to Weigh on MRK's Top Line in 2026? (Zacks)
07:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer (Business Wire)
02:30AM	ENHERTU Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer (Business Wire)
Mar-06-26 06:37PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
09:50AM	Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term (Zacks)
08:21AM	Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? (Zacks)
07:17AM	Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial (Proactive)
05:22AM	The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop (Zacks)
Mar-05-26 04:31PM	Top Analyst Reports for Exxon Mobil, Palantir & AstraZeneca (Zacks)
09:40AM	Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term (Zacks)
08:45AM	Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations? (Zacks)
06:00AM	Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor (Benzinga)
Mar-03-26 08:03PM	Compugen Ltd (CGEN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
10:05AM	Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead? (Zacks)
Mar-02-26 06:51PM	Salesforce CEO touts company resilience amid software slump (TheStreet)
12:31PM	Compugen Ltd. Q4 2025 Earnings Call Summary (Moby)
08:23AM	As Investors Flee U.S. Equities, This Global ETF Is Outperforming (MarketBeat)
Feb-26-26 10:04PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
10:40AM	IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks (Zacks)
09:18AM	Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook (Zacks)
09:02AM	AstraZeneca has 'sector leading replacement power' to cope with 2030 patent cliff (Proactive)
08:30AM	Novavax, Inc. Q4 2025 Earnings Call Summary (Moby)
Feb-25-26 08:49AM	Can J&J Sustain Its Double-Digit Oncology Growth Streak? (Zacks)
05:05AM	GSK to Buy 35Pharma for $950 Million (The Wall Street Journal)
01:07AM	Tempus AI Q4 Earnings Call Highlights (MarketBeat)
Feb-24-26 06:01AM	Health Care Roundup: Market Talk (The Wall Street Journal)
Feb-23-26 06:35AM	AstraZeneca's Calquence plus venetoclax gains approval in US to treat CLL (Pharmaceutical Business Review)
05:56AM	Podcast: Which pharma and medtech companies came out on top in 2025 revenues? (Pharmaceutical Technology)
Feb-20-26 10:46AM	AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026? (Zacks)
08:02AM	FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer (Benzinga)
07:00AM	CALQUENCE plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting (Business Wire)
Feb-19-26 10:15AM	Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure (Zacks)
09:55AM	Why AstraZeneca PLC (AZN) is One of the Best Immunotherapy Stocks to Buy According to Hedge Funds (Insider Monkey)
Feb-18-26 11:20AM	Moderna stock surges as FDA reverses course, agrees to review new flu shot (Yahoo Finance)
10:46AM	Forget the Endless AI Stock Debate: This Outperforming Sector is the One to Watch Now (Barchart)
04:10AM	FTSE 100 Live: Index powers to new highs as inflation falls, defence in demand (Proactive)
Feb-17-26 08:57AM	AbbVie Down Since Q4 Earnings Report: How to Play the Stock (Zacks)
12:10AM	Inside Biotech: AstraZeneca halts generic diabetes pill launch in patent battle with Pharmacor (Proactive)
Feb-16-26 11:45AM	Merck Indicates Better Growth Visibility in Post-Keytruda LOE Period (Zacks)
05:00AM	Theranostics earmarked as the future of radiopharmaceuticals (Pharmaceutical Technology)
Feb-14-26 11:30AM	Why Wedbush Thinks Norway Could Be Key for This Quantum Computing Stock -- and the Entire Industry (Barchart)
Feb-13-26 08:07PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
10:45AM	Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory (Proactive)
07:00AM	Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine (Business Wire)
Feb-12-26 01:26PM	A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH (MarketBeat)
10:35AM	IRWD Rises 307% in 6 Months: Is This an Indication to Buy the Stock? (Zacks)
09:13AM	Here's What Lifted AstraZeneca PLC (AZN) in Q4 (Insider Monkey)
07:55AM	Upstream Bios stock drops 47% on verekitug Phase II asthma data (Clinical Trials Arena)
04:36AM	Sanofi says board has removed CEO Paul Hudson (AFP)
Feb-11-26 08:04PM	AstraZeneca PLC (AZN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) +5.87%

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZN

Astrazeneca plc

Upgrade your Finviz experience